Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in skin cancer (non-melanoma)
- Trial result
Skin cancer (non-melanoma)
Retifanlimab (PD-1) MAIC Suggests Lower Progression Risk vs Avelumab (PD-L1) in Metastatic MCC
Retifanlimab is an anti–PD-1 monoclonal antibody, while avelumab is an anti–PD-L1 antibody; this unanchored matching-adjusted indirect comparison (MAIC) contrasted individual patient data from Phase 2 POD1UM-201…
NCT03599713 - Trial result
Skin cancer (non-melanoma)
Neoadjuvant PD-1 checkpoint blockade is associated with longer EFS/OS in resectable periauricular cSCC vs upfront surgery
In a retrospective, age- and stage-matched tertiary-center series of periauricular cutaneous squamous cell carcinoma (pCSCC) treated 2005–2025, neoadjuvant immunotherapy (checkpoint blockade; drug(s) not specified in…
- New trial
Skin cancer (non-melanoma)
Phase 2 cemiplimab PD-1 checkpoint inhibitor with standardized immunosuppression in KTR advanced cSCC
Washington University School of Medicine’s CONTRAC-2 is a Phase 2, multicenter, open-label, single-arm trial using Simon’s optimal two-stage design to test whether cemiplimab (Regeneron Pharmaceuticals/Sanofi; a…
NCT07715734 Exploratory - Trial result Spotlight
Skin cancer (non-melanoma)
Pembrolizumab (PD-1) cuts MCC-specific relapse events in resected Merkel cell carcinoma, with signal for better distant control
Pembrolizumab is an anti–PD-1 checkpoint inhibitor tested as adjuvant therapy in the randomized Phase III STAMP trial (EA6174; NCT03712605) after complete resection of stage I (no SLNB) to IIIB Merkel cell carcinoma:…
NCT03712605 - Trial result Spotlight
Skin cancer (non-melanoma)
Cemiplimab (PD-1) + response-adapted definitive RT delivers 86% 18-mo EFS in unresectable LA cSCC (RAMPART)
Cemiplimab-rwlc is an anti–PD-1 monoclonal antibody; in RAMPART (Phase II, multicenter, single-arm; NCT05574101), it was given neoadjuvantly (2 doses then response-adapted), concurrently with definitive radiotherapy…
NCT05574101 - Trial result
Skin cancer (non-melanoma)
Cemiplimab (PD-1) Cuts Recurrence Risk in High-Risk Resected CSCC—Consistent Across Risk Features and RT Timing
Cemiplimab (Libtayo) is an anti–PD-1 antibody tested as adjuvant systemic therapy after surgery plus postoperative radiotherapy in the Phase 3, double-blind C-POST trial (NCT03969004). In this exploratory DFS update…
NCT03969004 - Trial result
Skin cancer (non-melanoma)
Neoadjuvant anti–PD-1 immunotherapy drives 54% pCR and improves 2-year EFS in resectable stage III–IV cSCC
In a single-institution retrospective series of resectable stage III/IV cutaneous squamous cell carcinoma treated 2010–2024 (n=300), neoadjuvant (NEO) anti–PD-1 immunotherapy (median 3 cycles) followed by surgery was…
NCT06568172 - Trial result
Skin cancer (non-melanoma)
Cosibelimab PD-L1 Delivers 50% ORR in Unresectable Locally Advanced cSCC
Cosibelimab is a high-affinity PD-L1 antibody evaluated at 800 mg IV every 2 weeks in the pivotal Phase 1 cutaneous SCC expansion cohort (NCT03212404). In unresectable locally advanced cSCC not amenable to curative…
NCT03212404 - Trial result Spotlight
Skin cancer (non-melanoma)
ALA-PDT (20% aminolevulinic acid + blue light) Delivers 100% Histologic Clearance in Facial cSCC in situ
In the single-center, investigator-initiated, open-label NCT06159842 study, patients with biopsy-confirmed facial cutaneous squamous cell carcinoma in situ (cSCCis/Bowen disease) received 2 cycles of 20%…
NCT06159842 - Trial result
Skin cancer (non-melanoma)
Avelumab + Cetuximab (PD‑L1 / EGFR) Halves Progression Risk vs Avelumab Alone in Advanced cSCC
Avelumab, an anti‑PD‑L1 IgG1, was paired with the EGFR antibody cetuximab in the Alliance A091802 randomized phase 2 trial (NCT03944941) enrolling 60 patients (57 evaluable) with unresectable or metastatic cutaneous…
NCT03944941 - Trial result
Skin cancer (non-melanoma)
Cemiplimab (PD-1) Boosts 2-Year DFS to 87% in High-Risk Post-Surgical CSCC
Cemiplimab, an anti-PD-1 antibody, was compared to placebo in the Phase 3 C-POST trial (NCT03969004) as adjuvant therapy after surgery, with or without radiotherapy, for high-risk cutaneous squamous-cell carcinoma…
NCT03969004
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.